Crossfit Charlotte-Blog

Insulin Therapy Increases Cardiovascular Risk in Type 2 Diabetes
By Andrew Hendel

How does insulin therapy (i.e., use of exogenous insulin) affect heart disease risk in persons with Type 2 diabetes?
This 2017 review provides a variety of evidence indicating the use of exogenous insulin increases both heart disease risk and overall mortality in Type 2 diabetics. This indicates use of insulin therapy should be discouraged unless absolutely necessary, particularly given the existence of alternative pharmaceutical and lifestyle tools to establish glycemic control without the use of insulin. More broadly, this evidence is consistent with the assertion (previously explored on that hyperinsulinemia directly increases morbidity and mortality and thus suggests optimal therapies to manage diabetes need to consider both blood glucose and insulin control.

This 2017 review argues insulin therapy in diabetics increases risk of heart disease and overall mortality and should be discouraged in light of effective alternatives.

Early research on the use of insulin treatment to manage diabetes found insulin improved outcomes and reduced cardiovascular risk (1). At the time of these earlier trials, however, there were few other tools known to help diabetics manage blood sugar levels. As a result, diabetics often initially presented with very high HbA1c levels, which were brought into a more moderate range via insulin therapy. This early research thus only informs the narrow judgment that achieving glycemic control through insulin therapy leads to more favorable outcomes than failing to achieve glycemic control at all.

More recent long-term trials have consistently demonstrated that the use of insulin increases cardiovascular risk and mortality in diabetics, often in a dose-dependent manner (2). The evidence includes the following:

  • The DIGAMI-2 trial found insulin treatment doubled risk of non-fatal CV events in diabetics (3).

  • ACCORD was stopped early when it was found that a therapy including use of insulin increased mortality. For each 1-unit/kg/d increase in insulin dose, CV risk increased two- to three-fold (4).

  • A Kaiser patient registry study found insulin exposure increased CV risk by 2.5 times, with patients with longer exposure to insulin having greater increases in risk (5).

  • The Saskatchewan Health Registry similarly found a dose-dependent relationship between insulin exposure and overall mortality, with patients on the highest doses of insulin having a 2.79-times-higher risk of death by any cause (6).

  • A study of 6,000 diabetic patients found a dose-dependent association between insulin and increased all-cause mortality, CV, and cancer (7).

  • A study of 63,000 diabetics found insulin use doubled CV risk within the first few months and tripled CV risk when used for more than six months (8).

  • In patients with advanced heart failure, insulin use quadrupled overall mortality (9).

  • In a very large cohort of diabetics (188,000), insulin users had more than twice the risk of end-stage renal disease as nonusers (10).

Figure 1: Moderate and high levels of insulin exposure double and triple risk of cardiovascular events in diabetics, respectively (11).

The review authors note these risk ratios may in fact be underestimates. Insulin is generally provided alongside insulin-sensitizing agents, such as metformin or thiazolidinediones, drugs that have been associated with reduced risk of cardiovascular disease and mortality (12). Thus, the specific effect of insulin therapy on cardiovascular and mortality risk may be worse than the estimates provided above.

Exogenous insulin is not similar to endogenous (i.e., produced by the body) insulin. Externally delivered insulin cannot respond to elevations of glucose as rapidly as endogenous insulin, and the dose provided often leads to temporarily supra-physiological insulin levels (i.e., higher insulin concentrations than the body would experience naturally). The authors argue exogenous insulin may increase CV and mortality risk through three mechanisms.

First, insulin dosing leads to recurrent hypoglycemic episodes, many of which will be asymptomatic (13). Hypoglycemia acutely increases risk of cardiovascular events and can cause vasoconstriction, ECG changes, angina, and sudden death (14). Hypoglycemia also stimulates inflammation and oxidative stress, which may lead to the features of the metabolic syndrome and cardiovascular disease linked to diabetes (15).

Second, over-insulinization leads to weight gain, dyslipidemia, inflammation, insulin resistance, and beta-cell exhaustion; the direct effects of hyperinsulinemia have been previously reviewed on (16). Acutely, hyperinsulinemia may induce endothelial dysfunction, inflammation, and hypertension, all of which increase cardiovascular risk (17). Very high insulin levels may shift the heart away from fat metabolism toward glucose metabolism, a change with potentially toxic consequences (18).

High insulin levels also increase adiposity, particularly in the peritoneum, the fat depot most closely linked to metabolic disease (19). It is well known that insulin therapy leads to weight gain in diabetics, many of whom are already overweight prior to beginning treatment; the degree of weight gain is proportional to the insulin dose used (20).

In recent years, a variety of both pharmaceutical and lifestyle therapies have been shown to support glycemic control in diabetic subjects without increasing insulin levels (21). These therapies, unlike insulin, have been linked to reduced cardiovascular and mortality risk. In light of these alternatives, the authors argue insulin therapy should be discouraged except in cases where these alternatives (some of which have been explored previously on are insufficient to establish glycemic control.


  1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes

  2. To the editor: Diabetes therapy and cardiac risk; Divergent effects of various diabetes drugs on cardiovascular prognosis; The safety profile of exogenous insulin in people with type 2 diabetes: Justification for concern; Glycemic control in type 2 diabetes: Time for an evidence-based about face; Intensive insulin for type 2 diabetes: The risk of causing harm; The time is right for a new classification system for diabetes: Rationale and implications of the beta-cell-centric classification schema; Intensified glucose lowering in type 2 diabetes: Time for a reappraisal; Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: Dose association with all-cause mortality, cardiovascular events and cancer; Insulin therapy in insulin resistance: Could it be part of a lethal pathway?; High daily insulin exposure in patients with type 2 diabetes is associated with increased risk of cardiovascular events

  3. Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: Experiences from an extended follow-up of the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study

  4. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial; Effects of intensive glucose lowering in type 2 diabetes – ACCORD group; The association between symptomatic, severe hypoglycemia and mortality in type 2 diabetes: Retrospective epidemiological analysis of the ACCORD study

  5. A1C and cardiovascular outcomes in type 2 diabetes: A nested case-control study

  6. Insulin use and increased risk of mortality in type 2 diabetes: A cohort study

  7. Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: Dose association with all-cause mortality, cardiovascular events and cancer

  8. Association between serious ischemic cardiac outcomes and medications used to treat diabetes

  9. Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure

  10. Insulin requirement is a risk factor for end-stage renal disease independent of hemoglobin A1C levels in Type 2 diabetes mellitus.

  11. High daily insulin exposure in patients with Type 2 diabetes is associated with increased risk of cardiovascular events.

  12. 10-year follow-up of intensive glucose control in type 2 diabetes; Association between insulin monotherapy versus insulin plus metformin and risk of all-cause mortality and other serious outcomes: A retrospective cohort study; Insulin provision therapy and mortality in older adults with diabetes mellitus and stable ischemic heart disease; Optimizing clinical outcomes resulting from glucose-lowering therapies in type 2 diabetes: Increased confidence about the DPP-4 inhibitors and continued concerns regarding sulphonylureas and exogenous insulin; The effects of dual-therapy intensification with insulin or dipeptidylpeptidase-4 inhibitor on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A retrospective cohort study; Novel glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycemia compared with insulin in patients with type 2 diabetes

  13. Insulin use and increased risk of mortality in type 2 diabetes: A cohort study; The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemia in patients with Type 1 and Type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control.

  14. Divergent effects of various diabetes drugs on cardiovascular prognosis

  15. Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance; Heart disease in diabetes: A microvascular disease

  16. Insulin therapy in insulin resistance: Could it be part of a lethal pathway?; Obviating much of the need for insulin therapy in type 2 diabetes mellitus: A re-assessment of insulin therapy safety profile; Mechanism of the mitogenic influence of hyperinsulinemia; Mechanisms of disease: Pathway-selective insulin resistance and microvascular complications of diabetes; Diabetes and atherosclerosis — the role of insulin; Insulin and atheroma: 20-yr perspective

  17. Mitogenic action of insulin: Friend, foe or frenemy?; Nitric oxide and mitochondria in metabolic syndrome; Endogenous hyperinsulinemia and exogenous insulin: A common theme between atherosclerosis, increased cancer risk and other comorbidities; The injurious effects of hyperinsulinism on blood vessels; Prolonged exposure to high insulin impairs the endothelial Pi3-kinase/akt/nitric oxide signaling; Vasculotoxic effects of insulin and its role in atherosclerosis: What is the evidence?; Insulin resistance: From bit player to centre stage; Mortality and other important diabetes-related outcomes with insulin vs. other antihyperglycemic therapies in type 2 diabetes; The kidney: An unwilling accomplice in syndrome X; Exogenous insulin use and hypertension in adult patients with type 2 diabetes mellitus

  18. Intensive insulin for type 2 diabetes: The risk of causing harm

  19. Abdominal obesity and metabolic syndrome; Insulin therapy and body weight, body composition and muscular strength in patients with type 2 diabetes mellitus

  20. Addition of biphasic, prandial or basal insulin to oral therapy in type 2 diabetes

  21. Glucose-lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: A report from the Euro Heart Survey on Diabetes and the Heart; Association between serious ischemic cardiac outcomes and medications used to treat diabetes; Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study: A randomized controlled trial; Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes




5:30AM - 8:00PM



5:30AM - 8:00PM



5:30AM - 8:00PM



5:30AM - 8:00PM



5:30AM - 8:00PM



9:00AM - 12:00PM






Tell Us What You Think